{"links":{"html":"https://www.erudio.com/reports/mist-nct03654833","json":"https://www.erudio.com/reports/mist-nct03654833.json","markdown":"https://www.erudio.com/reports/mist-nct03654833.md","mcp":{"server":"https://mcp.erudio.com/free","tool":"get_report_card","arguments":{"slug":"mist-03654833"}},"request":"https://www.erudio.com/contact?report=mist-03654833"},"offer":{"cited_commentary_sources":35,"verified_hcp_statements":227,"currency":"USD","delivery":{"checkout":"online","current_edition":"Emailed as soon as payment clears: downloads, a license key and a prompt that connects your AI agent through Erudio MCP. One key per email address holds every report bought with it.","refresh":"A purchase starts a check for new commentary. A new edition, if one results, is sent to the buyer at no charge."},"identities":{"adds":"Verified IDs for the clinicians in the report, led by the NPI, so a Medical Affairs team can connect the report's voices to the expert and insight records it keeps by NPI: also X, Bluesky, LinkedIn and web pages, ORCID and OpenAlex where verified, inline on each person card (identifiers.status included). Without the add-on, each card's identifiers.status says whether the person is verified. For scientific and insight use inside the organization, including non-promotional engagement such as advisory boards and scientific exchange under its own compliance process; not for promotional targeting. Every report already names and describes its speakers and includes CMS-reported financial relationships. Sample: https://www.erudio.com/report-sample.json","available_with":"12-month updates","cap_usd":1250,"identity_verified_people":10,"optional":true,"price_per_verified_person_usd":15,"price_usd":150,"product":"updates-12-identities","terms":"Priced on the identity-verified people in the edition at purchase; people verified later in the term come at no charge."},"one_off_usd":1250,"purchase":{"agents":{"free_mcp":"https://mcp.erudio.com/free","keys":"One license key holds every report: get_order returns it once paid (store it as a secret), send it as licence_key with every later create_order so new reports join it. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST /api/keys/recover) with the buyer's email sends it again.","mcp_flow":["1. search_reports: Find reports by trial, NCT ID, drug, indication or sponsor. Each result has its page URL and price.","2. get_report_card: Preview one report with the slug from search_reports: what it covers, its findings and limits, and the price of each product.","3. create_order: Order the current edition or weekly updates for your person. It returns the quote, a checkout_url for your person to pay by card and, when offered, a pay_url your own payment client can pay over HTTP 402 (MPP or x402). Nothing is charged until one is paid.","4. get_order: Once the order is paid, it returns the license key. Store the key as a secret and send it as licence_key with every later create_order, so one key holds every report.","5. read_report: Read the report in full or by section on https://mcp.erudio.com/mcp, with the key as Authorization: Bearer. get_report_changes shows what a newer edition changed."],"order_endpoint":"https://www.erudio.com/api/orders","order_request":{"buyer_email":"name@company.com","idempotency_key":"optional, one per purchase","licence_key":"optional: your key from an earlier purchase","organization":"optional","product":["edition","updates-3","updates-6","updates-12","updates-12-identities"],"report":"mist-nct03654833"},"steps":"Create the order (with licence_key if you hold one) and show checkout_url to your person to pay by card. If the order also returns pay_url, you can pay it yourself instead: POST pay_url answers 402 Payment Required with MPP or x402 offers for your payment client. Once paid, status_url (or get_order) returns the license key, the MCP setup and downloads."},"contact":{"email":"hello@erudio.com","form":"https://www.erudio.com/contact?report=mist-03654833","people":"Audun Utengen and Tom Lee, the founders","use_for":"Questions, invoices, purchase orders"},"methods":["card (Stripe Checkout)"],"people":"https://www.erudio.com/reports/mist-nct03654833","renewal":"Subscriptions are prepaid and do not renew automatically.","upgrades":"What the buyer already paid on this trial counts toward a longer plan: a one-off edition within 30 days, or an active plan at any time in its term. The buyer pays the difference; an upgraded plan keeps its original start, and an upgraded one-off starts the plan on payment. Order the longer product with create_order and the buyer's licence_key (or on the report page with the buyer's email); the quote shows the credit.","terms":"https://www.erudio.com/terms"},"size":"standard","size_rule":"Standard: 151–300 verified statements","updates_usd":{"3_months":2200,"6_months":3100,"12_months":4400},"volume_discounts":[{"min_subscribed_trials":10,"percent_off_updates":25},{"min_subscribed_trials":5,"percent_off_updates":15}]},"publication_state":"public","record":{"change":{"changed_finding_ids":{"reason":"No changed finding IDs recorded.","status":"none"},"last_checked_at":"2026-11-01T11:51:25.064856Z","notify_subscribers":false,"status":"corrected","summary":"Corrected to match the delivered report: the limitations; the sample findings; the report description. The trial's name is spelled as its investigators write it, “MiST” (NCT03654833), outside quotations (was “MIST”, “Mist”)."},"contents":{"aspect_coverage":{"assessment_incomplete":0,"discussed":13,"no_commentary_found":0},"aspects":[{"claim_count":7,"coverage":"discussed","id":"T1","registry_field":"outcomesModule.primaryOutcomes[0]","source_count":5,"title":"Primary endpoint: Disease Control Rate (DCR) at 12 Weeks Assessed by Modified RECIST 1.1, in Patients With Relapsed Mesothelioma."},{"claim_count":3,"coverage":"discussed","id":"T2","registry_field":"outcomesModule.secondaryOutcomes[0]","source_count":2,"title":"Secondary endpoint: Disease Control Rate (DCR) at 24 Weeks Assessed by Modified RECIST 1.1, in Patients With Relapsed Mesothelioma."},{"claim_count":10,"coverage":"discussed","id":"T3","registry_field":"outcomesModule.secondaryOutcomes[1]","source_count":7,"title":"Secondary endpoint: Objective Response Rate (ORR) at 24 Weeks Assessed by Modified RECIST 1.1, in Patients With Relapsed Mesothelioma."},{"claim_count":19,"coverage":"discussed","id":"T4","registry_field":"conditionsModule","source_count":4,"title":"Population and setting"},{"claim_count":36,"coverage":"discussed","id":"T5","registry_field":"armsInterventionsModule.armGroups","source_count":13,"title":"The comparison"},{"claim_count":3,"coverage":"discussed","id":"T6","registry_field":"armsInterventionsModule.interventions","source_count":3,"title":"Safety and tolerability"},{"claim_count":13,"coverage":"discussed","id":"T7","registry_field":"designModule","source_count":7,"title":"Design and conduct"},{"claim_count":35,"coverage":"discussed","id":"A1","source_count":12,"title":"PARP sensitivity, biomarker uncertainty and the NERO follow-up"},{"claim_count":24,"coverage":"discussed","id":"A2","source_count":10,"title":"Host biomarkers, tumor immune context and microbiome hypotheses"},{"claim_count":16,"coverage":"discussed","id":"A3","source_count":5,"title":"Relapsed immunotherapy alternatives, symptom benefit, sequence and cost"},{"claim_count":11,"coverage":"discussed","id":"A4","source_count":1,"title":"Diagnostic molecular information, selective sequencing and trial referral"},{"claim_count":28,"coverage":"discussed","id":"A5","source_count":8,"title":"Master protocols, genotype-directed development and SELECT"},{"claim_count":15,"coverage":"discussed","id":"A6","source_count":12,"title":"Participation, funding, treatment continuity and institutional support"}],"counts":{"cited_sources":46,"claims_by_expression_type":{"comparison":13,"experience":6,"interpretation":74,"opinion":33,"primary_context":49,"question":5,"restatement":31,"uncertainty":14,"unspecified":2},"claims_by_kind":{"objective_result":4,"protocol_statement":40,"publication_statement":27,"source_observation":156},"clinician_statements":11,"evidence_units":164,"findings":9,"organisational_accounts":10,"people_cited":13,"people_identity_verified":10,"people_total":14,"screened_sources":193,"verified_claims":227},"findings_index":[{"id":"F1","structure":{"claims":17,"claims_by_group":{"comparisons":2,"experience":0,"questions":2,"restated":4,"views":9},"has_counterview":true,"limitations":3,"links":{"context":4,"support":18},"ma_question":true,"named_voices":4,"passages":7,"sources":5,"sources_by_kind":{"commentary":2,"media":3}},"title":"MiST5 enthusiasm does not resolve niraparib’s contribution or treatment after prior immunotherapy"},{"id":"F2","structure":{"claims":19,"claims_by_group":{"comparisons":0,"experience":1,"questions":4,"restated":6,"views":8},"has_counterview":true,"limitations":3,"links":{"context":1,"support":20},"ma_question":true,"named_voices":2,"passages":12,"sources":6,"sources_by_kind":{"commentary":1,"media":4,"publication":1}},"title":"The MiST1 PARP signal is considered promising, but a clinically useful sensitivity marker remains unsettled"},{"id":"F3","structure":{"claims":13,"claims_by_group":{"comparisons":2,"experience":1,"questions":3,"restated":1,"views":6},"has_counterview":true,"limitations":3,"links":{"context":6,"support":13},"ma_question":true,"named_voices":3,"passages":11,"sources":3,"sources_by_kind":{"media":3}},"title":"Relapsed immunotherapy is supported despite negative comparative endpoints, with response and treatment sequence central to the reasoning"},{"id":"F4","structure":{"claims":9,"claims_by_group":{"comparisons":1,"experience":0,"questions":1,"restated":4,"views":3},"has_counterview":true,"limitations":2,"links":{"context":1,"support":11},"ma_question":true,"named_voices":2,"passages":6,"sources":4,"sources_by_kind":{"commentary":1,"media":2,"registry":1}},"title":"MiST3 leaves the added value of bemcentinib unresolved"},{"id":"F5","structure":{"claims":7,"claims_by_group":{"comparisons":1,"experience":0,"questions":0,"restated":2,"views":4},"has_counterview":false,"limitations":3,"links":{"context":0,"support":9},"ma_question":true,"named_voices":2,"passages":5,"sources":4,"sources_by_kind":{"commentary":1,"media":2,"publication":1}},"title":"MiST2 supports biological plausibility and further testing, not proven clinical superiority"},{"id":"F6","structure":{"claims":34,"claims_by_group":{"comparisons":4,"experience":0,"questions":7,"restated":7,"views":16},"has_counterview":true,"limitations":5,"links":{"context":3,"support":39},"ma_question":true,"named_voices":5,"passages":30,"sources":9,"sources_by_kind":{"commentary":2,"media":5,"publication":1,"registry":1}},"title":"Microbiome and immune-context findings are an explanatory opportunity, not yet a clinical selection or dietary rule"},{"id":"F7","structure":{"claims":11,"claims_by_group":{"comparisons":2,"experience":2,"questions":0,"restated":0,"views":7},"has_counterview":true,"limitations":2,"links":{"context":4,"support":15},"ma_question":true,"named_voices":2,"passages":12,"sources":1,"sources_by_kind":{"media":1}},"title":"Focused diagnostic information is favored over universal sequencing in the NHS discussion"},{"id":"F8","structure":{"claims":25,"claims_by_group":{"comparisons":0,"experience":1,"questions":1,"restated":4,"views":19},"has_counterview":false,"limitations":3,"links":{"context":2,"support":27},"ma_question":true,"named_voices":3,"passages":16,"sources":4,"sources_by_kind":{"commentary":1,"media":2,"registry":1}},"title":"MiST’s platform contribution is framed as feasible stratification and a route to stronger evidence"},{"id":"F9","structure":{"claims":9,"claims_by_group":{"comparisons":0,"experience":1,"questions":0,"restated":1,"views":7},"has_counterview":false,"limitations":3,"links":{"context":0,"support":9},"ma_question":true,"named_voices":7,"passages":8,"sources":7,"sources_by_kind":{"commentary":7}},"title":"A speaker participation and access attract support, but institutional optimism is not clinical consensus"}],"medical_affairs_question":"What evidence will separate added drug benefit, reliable patient selection and a research opportunity from a treatment strategy ready for broader use?","sections":{"analysis":[{"id":"section-1","level":2,"title":"1. MiST5: development enthusiasm versus added benefit and immune rechallenge"},{"id":"section-2","level":2,"title":"2. MiST1 and PARP inhibition: a signal without a settled sensitivity marker"},{"id":"section-3","level":2,"title":"3. Immunotherapy after chemotherapy: negative comparative evidence and the perceived value of response"},{"id":"section-4","level":2,"title":"4. MiST3: activity is not attribution of benefit to bemcentinib"},{"id":"section-5","level":2,"title":"5. MiST2: functional replacement, clinical activity and comparator expectations"},{"id":"section-6","level":2,"title":"6. Microbiome and immune context: explanatory hypotheses with important negative findings"},{"id":"section-7","level":2,"title":"7. Diagnostic work-up: useful focused information, selective sequencing and trial referral"},{"id":"section-8","level":2,"title":"8. Umbrella stratification: feasibility and biological learning before broader clinical claims"},{"id":"section-9","level":2,"title":"9. Participation and access: distinguish implementation, advocacy and clinical interpretation"},{"id":"section-10","level":2,"title":"Scope and coverage"}],"executive_summary":{"reason":"Reviewed narrative has no headings.","status":"unavailable"}},"study_design":"interventional, non randomized, parallel, phase2","trial_dimensions":[{"findings":[{"id":"F1","shared_claims":3},{"id":"F2","shared_claims":1}],"id":"T1","label":"Primary endpoint: Disease Control Rate (DCR) at 12 Weeks Assessed by Modified RECIST 1.1, in Patients With Relapsed Mesothelioma."},{"findings":[{"id":"F1","shared_claims":1},{"id":"F2","shared_claims":1}],"id":"T2","label":"Secondary endpoint: Disease Control Rate (DCR) at 24 Weeks Assessed by Modified RECIST 1.1, in Patients With Relapsed Mesothelioma."},{"findings":[{"id":"F1","shared_claims":3},{"id":"F2","shared_claims":1},{"id":"F4","shared_claims":1},{"id":"F5","shared_claims":1},{"id":"F6","shared_claims":1}],"id":"T3","label":"Secondary endpoint: Objective Response Rate (ORR) at 24 Weeks Assessed by Modified RECIST 1.1, in Patients With Relapsed Mesothelioma."},{"findings":[{"id":"F1","shared_claims":3},{"id":"F3","shared_claims":6},{"id":"F8","shared_claims":4}],"id":"T4","label":"Population and setting"},{"findings":[{"id":"F1","shared_claims":8},{"id":"F2","shared_claims":2},{"id":"F4","shared_claims":3},{"id":"F5","shared_claims":6},{"id":"F6","shared_claims":2},{"id":"F8","shared_claims":8}],"id":"T5","label":"The comparison"},{"findings":[{"id":"F1","shared_claims":1}],"id":"T6","label":"Safety and tolerability"},{"findings":[{"id":"F1","shared_claims":2},{"id":"F2","shared_claims":1},{"id":"F8","shared_claims":7},{"id":"F9","shared_claims":1}],"id":"T7","label":"Design and conduct"}]},"identity":{"accepted_at":"2026-11-01T11:51:25.064856Z","edition_number":1,"previous_run_id":{"reason":"First accepted catalog edition.","status":"not_applicable"},"previous_version":{"reason":"First accepted catalog edition.","status":"not_applicable"},"product_contract":"hcp-commentary-1","published_at":"2026-11-01T12:06:59Z","record_hash":"b87b6a9eccd92206fe29b29ffca38e9a8af34be419eb65ed17de1da955d1225d","release_hash":"8eff8817e524d873c5251bdbc11e47726ddf10f6d114c91510ba8e354448453d","report_id":"erudio-nct03654833","run_id":"358b10a1-2520-4678-af90-07adbc668810","schema_version":"5.0","slug":"mist-03654833","version":"1.0.0","version_reason":"initial"},"offer":{"bundle_eligible":{"reason":"Owner has not set bundle_eligible.","status":"not_set"},"license_ref":{"reason":"Owner has not set license_ref.","status":"not_set"},"request_route":{"reason":"Owner has not set request_route.","status":"not_set"},"single_edition":{"reason":"Owner has not set single_edition.","status":"not_set"},"updates":{"reason":"Owner has not set updates.","status":"not_set"}},"preview":{"abstract":"MiST evaluates targeted therapies for disease control in relapsed malignant mesothelioma; debate centers on niraparib’s added benefit and treatment after prior immunotherapy. The report cites three medical oncologists and speakers described in the sources reviewed for this edition as presenting MiST and authoring its results, or as involved in MiST. Further questions concern PARP sensitivity markers and the clinical use of microbiome findings. What evidence would establish added benefit and reliable patient selection, and distinguish research opportunities from treatment ready for broader use?","meta_description":"193 sources screened · 227 verified statements (11 from clinicians verified by NPI or staff page) from 46 sources · 9 findings. Updated Nov 1, 2026.","person_names_policy":"role_only","sample_findings":[{"cited_claim_ids":["claim-1bc8dc41792dafd94744","claim-2cfa71adc35e3f470d91"],"id":"F8","paraphrase":"In a podcast discussion of MiST’s platform, a speaker asked whether successful genotype-directed proof-of-concept work would require phase II or randomized evaluation.","source_channel":"podcast","source_date":"2024-04-01","title":"MiST’s platform contribution is framed as feasible stratification and a route to stronger evidence"},{"cited_claim_ids":["claim-17ed6c9f073d478f030c"],"id":"F2","paraphrase":"An X post asked whether rucaparib response in BAP1- or BRCA1-deficient mesothelioma differs between germline and somatic alterations.","source_channel":"x_thread","source_date":"2021-08-06","title":"The MiST1 PARP signal is considered promising, but a clinically useful sensitivity marker remains unsettled"}]},"publication":{"approved_at":"2026-11-01T12:06:59Z","approved_by":"Erudio publisher","corrections":[{"affected_ids":[],"date":"2026-11-01T12:30:15Z","summary":"Corrected to match the delivered report: the limitations; the sample findings; the report description. The trial's name is spelled as its investigators write it, “MiST” (NCT03654833), outside quotations (was “MIST”, “Mist”)."}],"rights_status":"cleared: short attributed excerpts with link-out; no-derivatives sources suppressed; role-only names in previews","state":"public"},"schema_id":"erudio.catalog_record","schema_version":"2.1","scope_and_limits":{"commentary_scope":{"basis":"Only the sources used in this report; not all HCPs or all public discussion.","has_known_gaps":true,"source_count":193},"does_not":["judge efficacy","estimate HCP prevalence or consensus","give treatment advice"],"known_gaps":["Discussion that does not name the trial may be missing from this edition.","For 1 recording, a transcript separated by speaker was not available, so quotes come from the original automatic transcript and may lack speaker labels.","1 cited commentary passage leaves a source question open, such as who was speaking. The report attributes no further than the source shows.","Some clinician views in the sources used in this report are not yet captured as evidence in this edition.","Some passages in the sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.","141 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.","Further source limits: discussion that describes the trial without naming it may be incomplete; some discussion that describes the trial without naming it may be missing; sources about other trials are not included.","The sources reviewed for this edition are not a representative sample of all HCP opinion, and source totals cannot be interpreted as numbers of independent clinicians.","Some relevant discussion of access-dependent sequencing, biomarker-guided treatment choice and interpretations of CONFIRM is not fully represented. Other potentially relevant passages were not examined in detail.","The October 2023 comparison of genomic and immune-context findings, sampling timing and explanation of T-cell recruitment is incompletely represented. The April 2024 account of treatment choices after first-line immunotherapy is also incomplete. These gaps limit interpretation of the host-biomarker rationale and the relapsed-treatment sequence.","Discussion that used unfamiliar spellings or did not name the trial may be absent. One recording had limited transcript confirmation.","Several passages cannot be assigned to a named speaker. Conflicting names in some recordings leave identities unresolved; programme participation alone does not resolve ownership of the words.","Many views come from people described in the sources as presenting, authoring or participating in MiST. Those descriptions do not make their opinions independent validation or establish consensus.","Some speakers' identities or clinical roles are not established in the sources used in this report; each statement is attributed only as far as its source shows.","Early single-arm activity, historical or cross-trial comparisons and exploratory biological associations do not establish incremental benefit, treatment equivalence or a validated selection rule.","A speaker’s MiST5 conclusion conflates 12-week and best-response disease control. Informal descriptions of MiST4’s partner drug or checkpoint class also differ from its protocol; each has been preserved as an attributed statement rather than silently corrected.","Statements about treatment standards, access, future trial starts and anticipated presentations belong to their original time and jurisdiction. Dates do not establish a change of mind, and intervention-specific regulatory labeling is not comprehensively established here.","Not yet captured in this edition: a view on precision-medicine development and synthetic-lethal treatment approaches for relapsed mesothelioma.","Not yet captured in this edition: a question about biomarkers guiding treatment selection in relapsed mesothelioma.","Not yet captured in this edition: a view on access-dependent sequencing of chemotherapy and immunotherapy in mesothelioma.","Not yet captured in this edition: a view on genomic versus immune response biomarkers, pretreatment sensitivity and uncertainty about T-cell recruitment.","Not yet captured in this edition: a view on second-line treatment options for previously treated mesothelioma."]},"sources":{"cited_sources":{"by_channel":{"bluesky_thread":0,"linkedin_post":0,"other":0,"podcast":5,"publication":4,"registry":7,"regulatory":0,"x_thread":24,"x_video":0,"youtube":6},"by_evidence_role":{"commentary":35,"methods":8,"results":3},"count":46,"evidence_window":{"end":"2026-09-14","start":"2018-06-29"},"retrieval_snapshot":"2026-10-31T05:04:07.210087Z","timeline":[{"count":1,"week":"2018-W26"},{"count":2,"week":"2018-W27"},{"count":2,"week":"2019-W06"},{"count":1,"week":"2019-W25"},{"count":1,"week":"2019-W40"},{"count":1,"week":"2019-W41"},{"count":1,"week":"2019-W44"},{"count":1,"week":"2020-W22"},{"count":1,"week":"2020-W24"},{"count":1,"week":"2020-W27"},{"count":2,"week":"2021-W04"},{"count":1,"week":"2021-W05"},{"count":2,"week":"2021-W16"},{"count":1,"week":"2021-W18"},{"count":1,"week":"2021-W24"},{"count":1,"week":"2021-W31"},{"count":1,"week":"2022-W06"},{"count":1,"week":"2023-W14"},{"count":1,"week":"2023-W23"},{"count":1,"week":"2023-W31"},{"count":1,"week":"2023-W42"},{"count":1,"week":"2024-W14"},{"count":3,"week":"2024-W22"},{"count":1,"week":"2024-W24"},{"count":2,"week":"2024-W25"},{"count":1,"week":"2024-W39"},{"count":1,"week":"2025-W18"},{"count":1,"week":"2026-W38"}],"undated_sources":11},"quote_policies":[{"id":"clinicaltrials:NCT03654833:methods","quote_policy":"short_quote_link_out"},{"id":"clinicaltrials:NCT03654833:results","quote_policy":"short_quote_link_out"},{"id":"clinicaltrials:NCT03654833:context","quote_policy":"short_quote_link_out"},{"id":"clinicaltrials:NCT03654833:protocol:1","quote_policy":"short_quote_link_out"},{"id":"clinicaltrials:NCT03654833:protocol:2","quote_policy":"short_quote_link_out"},{"id":"clinicaltrials:NCT03654833:protocol:3","quote_policy":"short_quote_link_out"},{"id":"clinicaltrials:NCT03654833:protocol:4","quote_policy":"short_quote_link_out"},{"id":"clinicaltrials:NCT03654833:protocol:5","quote_policy":"short_quote_link_out"},{"id":"clinicaltrials:NCT03654833:protocol:6","quote_policy":"short_quote_link_out"},{"id":"clinicaltrials:NCT03654833:sap:7","quote_policy":"short_quote_link_out"},{"id":"pubmed:33515503","quote_policy":"short_quote_link_out"},{"id":"pubmed:35157829","quote_policy":"short_quote_link_out"},{"id":"pubmed:37993149","quote_policy":"short_quote_link_out"},{"id":"pubmed:39168966","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-4ayq4hzag3fnmpifd35fwoey-3lbkhd4vvsc2i","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-dx25eryz76cwhwleqoouhec7-3ml4uyu3xoc2h","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-ec63mmy2zso7guocicqfu37a-3mx2pue35rs2p","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-fa3rwygrp2ebgwdiq6sjn2te-3l76qweg5nh2m","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-fh46osoisvixxbrqbpeiqtby-3lgbxd3mits2q","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-g4a7su5twxxhfzp3inwu5yt3-3jzwt6vxoyw25","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-h4kyplwqa736kgmqocluwwq5-3mculcvhavg25","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-h4kyplwqa736kgmqocluwwq5-3mdayml2dnq2a","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-h4kyplwqa736kgmqocluwwq5-3mg5psrrzij2s","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-i7g62qhqwyobrqzg63yyz7vf-3lvhcg4r3vk22","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-iwbebt5r65c67xl5vy5iviwj-3mfwvpyfi7k23","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-l3p636v5hffkebngf5szed3j-3lmfq7zlfrk2g","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-om53ubbzjijpmezyry7ffeqc-3lkle2cvvec2j","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-oukyua3y5spw3ptwirlidvcw-3lkbmiuszak2e","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-ozkvd6djihrjmimal56dve6w-3ktztg57epc22","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-ozkvd6djihrjmimal56dve6w-3kwrfyekxpe2v","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-ozkvd6djihrjmimal56dve6w-3lofhhsqth42n","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-qfp3ijfpjif4i33pl4nnnrj4-3mblj5qilb22w","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-qmkh5xkfn7lbyh5suv2aiqqy-3lxklysw7hc2b","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-qw6djsufo4wezhpoqrrmpdek-3mwxcvd2ywj2g","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-rk6u6sj7ci4ykibjttqadjhw-3mszmbc5tzc2w","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-sjzdgockznfxek63acppuuxu-3lefcrfguqk2j","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-sqmwodqbqmn46fw4ubnlgpl4-3m55l7fowhk2z","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-sx6bg2olo7zncowe67lwhsnw-3lefioruips2m","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-xtkxi3lh5gyaal7hyn2xmlzo-3ly3sp56uds2d","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:1f9a5d","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:2ed23e","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:2f394e","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:43918b","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:4b98bd","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:5624d1","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:5814b3","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:6d4c2e","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:86359b","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:88361f","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:9ccac2","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:c81ba7","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:ca59ea","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:caaf67","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:cb6199","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:f72439","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:f833cc","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1012643516953104384:4b89918b-40ec-488e-b118-b57941c0c715","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1015178063607422976:23cf28fc-4ceb-4c11-95f2-726c181699f3","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1015254105109991426:a7c3542e-dad5-4914-803c-969a1d44ae51","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1047413829162999808:dd541abc-bf6b-4a18-b603-c2d76c4aabe8","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1047428786239819776:fed72848-234c-49ff-bffa-b75eaf199ba0","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1055219262837669888:43fe5059-8461-4946-a8fa-8607967f6b95","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1062236118437875712:a665b7c3-5536-4790-b7f6-faecb70e8c2d","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1084021473306648576:2f2fd073-dc3a-4a4c-ab71-30ff27247976","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1088472747230023682:4db95eed-bd2e-4c10-a2d5-5568a4e760e3","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1089078003714408448:efbefea9-ee0d-423a-9c38-1f2f2f93fce1","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1089261833737981954:0140b64e-a01e-4029-9033-f7154d2220d9","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1090286967517036544:541396e9-c555-4ecc-b86c-4da49fc308aa","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1092430109989060609:ac4e13c0-785e-4660-b0fd-509afb705ceb","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1093132382511734786:f45c452d-de5b-40b6-8611-2ff41494eac6","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1093223000919494656:4e7a8b4c-3dd4-42e6-9e06-a2aa7f08fb7e","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1096370225753264128:ddd20805-9bfc-473c-9597-4376aea0ce21","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1140625104516374532:1b583fb9-f94e-4b37-8f9f-4f58e11ebae1","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1157208256525283329:805f05f4-bb04-4987-a252-eb3b2c0b0c6f","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1161018083651145729:ddf8b7ee-76c6-4c0f-8f57-c998e5010e18","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1171130889436377088:0f4b957e-baa8-4484-a09c-f5733913a8fc","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1179272819072479235:efca9a8f-7bd8-4aae-b734-bfdc72fe0f2e","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1180075007923408896:4cdef186-5482-436c-b622-3a5eac256490","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1183068705351184386:2c94ff57-8d81-4e04-820f-e45babdffe39","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1183835146086170625:18b7ebf8-ffbd-4ddc-b49a-026e86694867","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1187781045111930880:342e848b-6e1c-4098-b4d8-ba0e484b88fb","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1189272605930471425:490a36ff-987c-4882-aa4b-7fb40e92839e","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1192777804607361030:637319d9-4602-45e3-ae5b-1aceb86a7d78","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1196790551842045952:fbdff283-b713-48b8-a42e-d9b5080b8e69","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1196791642860199937:ae3eee27-a312-49cf-91ce-9dfaa149d74b","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1220424072322068481:5caf7d43-90a2-4753-8c95-140092ec8a2c","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1223215021930565633:75ef2efc-590f-4011-91e4-01dab82d21e8","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1223215189199392768:e5618a71-25f0-4370-88bd-d6d061b2c7cb","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1223223985686700032:a9e944f8-f01c-41dd-9749-819e54591817","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1234286067760664576:c08a67f3-476a-4463-bb05-7f2ebc497ae1","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1240711257377746944:a3a2c374-32f4-4b8c-8dd3-fc531c6d9b80","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1242300380714881024:bc8d976b-e257-445a-a93a-e756430a08f0","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1263926598350372864:ee7c025e-c486-45fe-ac23-5bc48908a293","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1266382556238356481:1f9477a7-b417-4d08-93e9-f534136448f4","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1275749513760845825:1a158e52-69e1-4b6b-803c-e505dae87bca","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1276323551432278023:0cf310d4-432d-47d5-931e-f5edf3636a91","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1279044179159650307:0ad6754c-2b8b-49c9-810a-5e0616286e92","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1287444559539052544:03937d6a-5861-4a0e-8292-4b4ef137525a","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1289180475873845248:bf7af50e-25e1-4110-903e-73a71a4fabe5","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1293136206197383176:d2d01af8-93ce-41f5-aee0-2ce992055a3d","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1294803047059775494:03a76af9-911a-41ee-8fc1-4201f5483175","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1309409934170357760:9c80d967-40cb-41ea-8711-556ab8e43767","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1326548447604822021:9aca4d1c-d965-490a-b408-941a6abbe9a4","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1348619262211072001:105add9a-29ca-41d9-b35f-45a8219fd418","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1354705381134643200:68290278-3683-4de5-a169-c8d775e73099","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1355310999960768517:d6cf1534-64d8-459e-b1f0-a5ef140ca66e","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1355561609423413254:a83e706c-47d2-4747-93e2-7598153eb012","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1357247849268920321:eef7cbf4-fd4b-48ab-917b-26f49db48734","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1385288336625991688:fa3dbedf-6677-44fb-ba1d-245ebf1b4398","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1385581723145015309:c908cd46-61d3-4282-a337-dffe4751479d","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1385584050929291264:3bacba72-c16d-4ffb-9b46-393e3e1fbfcb","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1386642344116633600:b416853e-8c06-4370-a16e-6813868b1962","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1390211693972795393:fcada432-142a-4509-80bb-afb9b68d0149","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1391364362900844544:9b70a870-3011-4867-9ecb-3419883829e0","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1405182149033140233:c6e84064-58dd-4eed-a4e3-4dfea1cef557","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1423471503765491716:b696df84-b141-4e50-8f08-eafb01e5d0db","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1485348971186896902:56e8f00a-a0d6-4d64-82a2-dfa0e1eea31f","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1486753371566469123:778ad21b-a072-4c0c-9654-a3e7798ac4f4","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1486753522867707906:ff53d90f-df33-44c1-ba8d-cb9b910c04c8","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1492284765432651776:ba5eee5d-b47d-4e83-a02d-82beecc27dd3","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1497266332898717696:9d4bc0f4-bca0-4deb-8b01-28d7b01b4cdf","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1524049052958081034:636089ea-9c55-4823-899c-4029bf8c8042","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1629858537965854720:dd6d79be-75c7-4fdc-bbca-2e6e16412e82","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1642841510734446593:802d7310-4589-480d-8f79-ea752e85f258","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1649479185222475799:ebb961ab-eb4f-42a5-86ac-1ffa2409d4c7","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1651226455756492802:0a4f6428-3ab8-466b-9d83-1faa2434c815","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1656075054239608835:9c9d80cd-b094-4607-954e-bfe3b8e5e0ed","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1657797845360025600:4948ce72-8ca0-418b-a8ec-78217354e0f0","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1661771135581663238:6447c33c-602f-4fb8-80d3-787465fb0605","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1665690587910004738:9028f88b-a4e5-4219-8c62-88b6aa25d803","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1665766206928740353:83b30314-76fd-4d7b-a569-63d40cf63734","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1665766415964545026:7b527f1b-8222-47d2-9e9a-774c64cb2679","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1665766712459816961:970b672d-44fb-4bb9-8cbf-5fc1275cf35f","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1665767260202434560:5a58f4b6-2852-48a2-b396-7c909460e90e","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1666031611593342977:cede2c60-1f63-4654-a61f-3eb3201ba896","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1674030527517540352:8916d1cf-057d-4ac3-b014-d7b16ab5c63e","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1700497206522880287:43bf8c71-8540-4f80-95d7-d824b3ce92a4","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1766524160920969441:987266c9-23ae-43bf-8dd1-aa304fc22cc0","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1768964244328907192:dd548f23-ea49-4e38-ba54-4fa4f7971fec","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1779591006658179433:4f855c7c-9204-4f8e-8c1c-e4d2b6a7efdf","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1783146069213470824:ca089f1f-dd6c-4bf1-b113-04ba656efded","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1783417879523647869:7ea99099-ae26-4147-9a82-b57d6b6f3bda","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1797399264303124808:b1d48ae6-ca18-4ea2-890a-ba7b34b4280b","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1797399420532580723:d1766e53-46fb-45a7-91ef-a6ef1df603b1","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1797399842320232782:b5a5a013-c89a-4189-a23a-910eb9c22304","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1797405714081628273:ef32b1e3-ab4d-4264-a88c-951c2d2d403a","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1802734221859144106:63e89c25-6f3c-484f-9e19-48925a8748a1","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1824216144225636450:1914a966-eb12-4db1-9a88-4761749fe1c1","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1835248962833399881:10021ca7-c1c5-48f3-9646-0cc0d3b779bf","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1835578113427980426:9915aa28-20c7-40bb-b5cf-e0e156702c33","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1839325773343396041:b9eaa787-6882-44b3-a5be-53f495035914","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1843575413181964587:dcf02759-2909-462c-88f6-342d7f21ad4c","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1865047901379932183:f2e23f04-5701-4191-becb-e7ddec617d18","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1866104911055778114:26501c26-2f2b-4ff5-bed0-a8179dca4bc9","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1866105658044481674:1ad989d6-ab06-4d23-bd67-cffaf8936f61","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1866106190217789524:7b7fad5c-ca6b-4f20-9ce1-b67cdb1ac4fd","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1880090726777905584:915da26d-fcae-4d0b-a102-f9841e730afb","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1911071547558707689:d2fbeca0-6d33-4817-9d74-4b1a65a1b096","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1911407200594985450:60fad20d-066a-4f36-b48c-7b1f676edf0e","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1914695697108230494:d8062bac-804c-4f53-9e04-350578653585","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1915058096226865275:cea1d67a-3ff1-4e5b-bac4-3aca3091c2fd","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1915782868032164295:0267ea22-9280-4160-9aac-e26a9dd10915","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1916280992807194778:2c4fcf6b-36bd-4ac4-8b2d-28978664ac08","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1924331879052030069:dbd69d10-cc4b-4faa-ace3-6cdef913bcbd","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1925612791920009370:73ee32b1-128a-4ca2-bc3d-e8b067d81ec3","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1940104630480011338:066cac74-4584-410c-8bb2-32449b7f7133","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1955291504831816092:aa7dace9-3d7f-40c5-b0cd-d1d958b103f3","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1966100137312231443:bf687f43-97fd-4d67-a658-d0196eb8c465","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1981237254778737049:927bb52b-c331-4524-9648-1cbdbf5bffd9","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1982121957916061703:e3888a07-5c18-43e6-a682-3d2300a158f9","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2001641206682640794:f333b4e8-9f18-4658-b8b7-79d3a232318b","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2009084434981769506:b8264d35-1590-4d94-b29b-54cfc69368da","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2032956682352120212:2b498927-204b-480d-8fe9-33f14d69fa35","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2038396428146348164:3ee7583f-796e-47d9-8cb7-62792668ce12","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2043015107819561184:0a590b84-2499-42a0-8ebe-003f11ba9264","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2051354089414705217:f3a9daa9-f3d1-49ad-bc1d-c501c087684c","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2059853284240670870:cfcbb70d-b8e1-493a-9126-31c15da53f1b","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2092249694030422239:10dcf243-c598-4b67-9423-9a2d4225127d","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2094821157333557633:21c3a1c5-f17b-48cc-b7f0-e2d4daaf2c7b","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2098592421122847136:e2eb5b64-a77b-4282-82cf-94c5dbe16ef0","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2100842335776948607:8c3ec39d-aed9-4c37-ae3c-e5d0166ebf3f","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2100946007513063799:6c1576c5-b5bd-4ea7-ac9c-60663a27bcec","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2106000280642875770:c0fd53b2-6c5a-4ce1-b05a-4bd1e25e015b","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2109630365396836371:84834ec8-5afc-408a-828d-3ef0caac73af","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2113791648958144597:89a86542-67c5-4749-9417-20019048d9fa","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:969014616410992640:b134b9e1-e71c-4798-88ff-c5d6c9cd40ae","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:969638513003069448:c4c6738a-b401-4b28-837c-333b17ed42de","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:971718788767924224:d2c571ed-5b9b-4bb5-a2f3-6e042aa38b27","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:974276614107357190:598d8818-b4d0-4069-b3c4-edabad0b9c0d","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:989435988261920768:ac5dfd9d-1ff8-4bf6-bcd3-442e40ff3a0b","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:998386869896347648:9a7e7bd1-1621-4ded-99a6-a1d94e327962","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:998877053578604544:4ca0d2fd-b458-493d-b2e5-e625ef044a03","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:2Rw4r7pZJiY","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:2f_Xh1paVts","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:38mVbYH5I_A","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:44Uv1gzlCH4","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:5V-7Du_N5kc","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:9Wvf9SSTziY","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:JiT-ZfcBhvc","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:JqTZTAWuBuY","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:OM7oPzU8We8","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:Q1H-G6mA3Xo","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:S8rT7JGDmrs","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:XWZ1IlkpSVQ","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:d0uLVklYAIM","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:mVd3mHlLYaM","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:x_HdfFadCBY","quote_policy":"short_quote_link_out"}],"screened_sources":{"by_channel":{"bluesky_thread":25,"linkedin_post":0,"other":0,"podcast":17,"publication":0,"registry":0,"regulatory":0,"x_thread":136,"x_video":0,"youtube":15},"by_evidence_role":{"commentary":193},"count":193,"evidence_window":{"end":"2026-10-24","start":"2018-03-01"},"retrieval_snapshot":"2026-10-31T05:04:08.773219Z","timeline":[{"count":2,"week":"2018-W09"},{"count":1,"week":"2018-W10"},{"count":1,"week":"2018-W11"},{"count":1,"week":"2018-W17"},{"count":2,"week":"2018-W21"},{"count":1,"week":"2018-W26"},{"count":2,"week":"2018-W27"},{"count":2,"week":"2018-W40"},{"count":1,"week":"2018-W43"},{"count":1,"week":"2018-W46"},{"count":1,"week":"2019-W02"},{"count":3,"week":"2019-W04"},{"count":1,"week":"2019-W05"},{"count":3,"week":"2019-W06"},{"count":1,"week":"2019-W07"},{"count":1,"week":"2019-W25"},{"count":1,"week":"2019-W31"},{"count":1,"week":"2019-W33"},{"count":1,"week":"2019-W37"},{"count":2,"week":"2019-W40"},{"count":1,"week":"2019-W41"},{"count":1,"week":"2019-W42"},{"count":1,"week":"2019-W43"},{"count":1,"week":"2019-W44"},{"count":1,"week":"2019-W45"},{"count":2,"week":"2019-W47"},{"count":1,"week":"2020-W04"},{"count":3,"week":"2020-W05"},{"count":1,"week":"2020-W10"},{"count":1,"week":"2020-W12"},{"count":2,"week":"2020-W13"},{"count":1,"week":"2020-W21"},{"count":1,"week":"2020-W22"},{"count":1,"week":"2020-W24"},{"count":2,"week":"2020-W26"},{"count":1,"week":"2020-W27"},{"count":1,"week":"2020-W30"},{"count":1,"week":"2020-W31"},{"count":2,"week":"2020-W33"},{"count":1,"week":"2020-W39"},{"count":1,"week":"2020-W46"},{"count":1,"week":"2021-W02"},{"count":3,"week":"2021-W04"},{"count":2,"week":"2021-W05"},{"count":5,"week":"2021-W16"},{"count":1,"week":"2021-W17"},{"count":2,"week":"2021-W18"},{"count":1,"week":"2021-W24"},{"count":1,"week":"2021-W31"},{"count":1,"week":"2022-W03"},{"count":2,"week":"2022-W04"},{"count":1,"week":"2022-W06"},{"count":1,"week":"2022-W08"},{"count":1,"week":"2022-W19"},{"count":1,"week":"2023-W08"},{"count":1,"week":"2023-W09"},{"count":1,"week":"2023-W14"},{"count":1,"week":"2023-W16"},{"count":1,"week":"2023-W17"},{"count":1,"week":"2023-W18"},{"count":2,"week":"2023-W19"},{"count":1,"week":"2023-W21"},{"count":1,"week":"2023-W22"},{"count":6,"week":"2023-W23"},{"count":2,"week":"2023-W26"},{"count":1,"week":"2023-W27"},{"count":1,"week":"2023-W31"},{"count":2,"week":"2023-W33"},{"count":1,"week":"2023-W36"},{"count":1,"week":"2023-W42"},{"count":1,"week":"2023-W49"},{"count":2,"week":"2024-W07"},{"count":1,"week":"2024-W08"},{"count":1,"week":"2024-W09"},{"count":2,"week":"2024-W11"},{"count":1,"week":"2024-W14"},{"count":1,"week":"2024-W15"},{"count":2,"week":"2024-W17"},{"count":4,"week":"2024-W22"},{"count":1,"week":"2024-W23"},{"count":1,"week":"2024-W24"},{"count":3,"week":"2024-W25"},{"count":1,"week":"2024-W28"},{"count":1,"week":"2024-W33"},{"count":1,"week":"2024-W37"},{"count":1,"week":"2024-W38"},{"count":1,"week":"2024-W39"},{"count":1,"week":"2024-W41"},{"count":2,"week":"2024-W43"},{"count":1,"week":"2024-W45"},{"count":1,"week":"2024-W47"},{"count":1,"week":"2024-W49"},{"count":3,"week":"2024-W50"},{"count":1,"week":"2024-W51"},{"count":2,"week":"2024-W52"},{"count":1,"week":"2025-W03"},{"count":1,"week":"2025-W04"},{"count":1,"week":"2025-W11"},{"count":1,"week":"2025-W12"},{"count":4,"week":"2025-W15"},{"count":4,"week":"2025-W17"},{"count":1,"week":"2025-W18"},{"count":1,"week":"2025-W19"},{"count":2,"week":"2025-W21"},{"count":1,"week":"2025-W22"},{"count":1,"week":"2025-W27"},{"count":2,"week":"2025-W31"},{"count":1,"week":"2025-W33"},{"count":1,"week":"2025-W35"},{"count":1,"week":"2025-W36"},{"count":1,"week":"2025-W37"},{"count":1,"week":"2025-W38"},{"count":1,"week":"2025-W40"},{"count":2,"week":"2025-W43"},{"count":1,"week":"2025-W45"},{"count":1,"week":"2025-W46"},{"count":1,"week":"2025-W51"},{"count":1,"week":"2026-W01"},{"count":1,"week":"2026-W02"},{"count":2,"week":"2026-W04"},{"count":1,"week":"2026-W09"},{"count":1,"week":"2026-W10"},{"count":1,"week":"2026-W11"},{"count":1,"week":"2026-W13"},{"count":1,"week":"2026-W15"},{"count":2,"week":"2026-W19"},{"count":3,"week":"2026-W22"},{"count":1,"week":"2026-W23"},{"count":1,"week":"2026-W28"},{"count":1,"week":"2026-W33"},{"count":1,"week":"2026-W35"},{"count":1,"week":"2026-W36"},{"count":1,"week":"2026-W37"},{"count":3,"week":"2026-W38"},{"count":3,"week":"2026-W40"},{"count":1,"week":"2026-W42"},{"count":1,"week":"2026-W43"}],"undated_sources":0}},"taxonomy":{"biomarkers":{"reason":"No structured, checked-in biomarker mapping for this trial.","status":"unmapped"},"conferences":{"reason":"No conferences in source metadata.","status":"none"},"drugs":[{"reason":"Unmapped registry intervention: rucaparib","status":"unmapped"},{"brand_names":["Verzenio"],"label":"abemaciclib","slug":"abemaciclib"},{"reason":"Unmapped registry intervention: pembrolizumab & bemcentinib","status":"unmapped"},{"reason":"Unmapped registry intervention: atezolizumab & bevacizumab","status":"unmapped"},{"reason":"Unmapped registry intervention: dostarlimab and niraparib","status":"unmapped"}],"indications":[{"reason":"Unmapped registry condition: Mesothelioma, Malignant","status":"unmapped"}],"line_of_therapy":{"reason":"No structured, checked-in line-of-therapy mapping for this trial.","status":"unmapped"},"therapeutic_area":{"reason":"Conditions lack a therapeutic-area mapping.","status":"unmapped"}},"trial":{"acronym":"MiST","aliases":["MiST","Mesothelioma Stratified Therapy (MiST) : A Multi-drug Phase II Trial in Malignant Mesothelioma","Mesothelioma Stratified Therapy (MiST): A Stratified Multi-arm Phase IIa Clinical Trial to Enable Accelerated Evaluation of Targeted Therapies for Relapsed Malignant Mesothelioma"],"brief_title":"Mesothelioma Stratified Therapy (MiST) : A Multi-drug Phase II Trial in Malignant Mesothelioma","collaborators":["British Lung Foundation","Clovis Oncology, Inc.","Eli Lilly and Company","Merck Sharp & Dohme LLC","BerGenBio ASA","Roche Pharma AG","University Hospitals, Leicester","The Christie NHS Foundation Trust","GlaxoSmithKline"],"conditions":["Mesothelioma, Malignant"],"display_condition":"relapsed malignant mesothelioma","display_interventions":[["rucaparib"],["abemaciclib"],["pembrolizumab","bemcentinib"]],"enrollment":{"count":186,"type":"ACTUAL"},"interventions":[{"name":"Rucaparib","synonyms":["CO-338"],"type":"DRUG"},{"name":"Abemaciclib","synonyms":["LY2835219"],"type":"DRUG"},{"name":"pembrolizumab & bemcentinib","synonyms":["Keytruda; BGB324"],"type":"DRUG"},{"name":"Atezolizumab & Bevacizumab","synonyms":["MPDL3280A; Avastin"],"type":"DRUG"},{"name":"Dostarlimab and Niraparib","synonyms":["Zejula"],"type":"DRUG"}],"nct_id":"NCT03654833","official_title":"Mesothelioma Stratified Therapy (MiST): A Stratified Multi-arm Phase IIa Clinical Trial to Enable Accelerated Evaluation of Targeted Therapies for Relapsed Malignant Mesothelioma","other_names":[{"kind":"also","name":"MiST3"}],"overall_status":"COMPLETED","phase":["PHASE2"],"primary_completion_date":{"date":"2023-02-21","type":"ACTUAL"},"primary_endpoints":[{"description":"This will be assessed using CT scan evidence according to modified RECIST 1.1 criteria reporting. Scans will be undertaken every 6 weeks. Analysis will be timed from study entry using the baseline CT scan results until completion of treatment cycles, confirmed disease progression or death-whichever comes first. Complete response (CR): disappearance of all target and non-target lesions with no evidence of tumour elsewhere Partial response (PR): reduction of at least 30% in the sum of all measurements with no evidence of significant disease progression in non-target lesions or new lesions Progressive disease (PD): 1: increase of at least 20% in the sum of all measurements compared with the previous best response, 2: appearance of one or more significant (overall 20% increase in tumour diameters) new lesions, 3: significant increase in target lesions Stable disease (SD): neither sufficient shrinkage to qualify for PR, nor sufficient increase to qualify for PD","measure":"Disease Control Rate (DCR) at 12 Weeks Assessed by Modified RECIST 1.1, in Patients With Relapsed Mesothelioma.","timeFrame":"12 weeks"}],"registered_date":{"date":"2018-08-31","type":"ACTUAL"},"registry_last_updated":"2026-08-17","registry_url":"https://clinicaltrials.gov/study/NCT03654833","short_name":"MiST","short_name_basis":"registry_acronym","sponsor":"University of Leicester","start_date":{"date":"2019-01-28","type":"ACTUAL"},"study_design":"interventional, non randomized, parallel, phase2","study_ids":[{"id":"0627","type":"sponsor_study_id"}],"study_type":"INTERVENTIONAL"}}}